'
Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD
Leuven, BELGIUM - May 6, 2024 - 6:00 PM CET, Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, today announces important progress in its preclinical program targeting Geographic Atrophy (GA), a severe and underserved form of Age-Related Macular Degeneration (AMD).
This recently launched program has reached the first step with the identification of 50 targets that have the potential to provide better treatment options for GA. These targets are derived from a cutting-edge CRISPR-based target discovery platform, which consists in a genome-wide screening in a phenotypic cellular assay reflective of GA disease.
The preclinical team successfully already confirmed the potential of several of these targets across various relevant in vitro models. Next step is to continue the in vitro validation of the remaining identified targets and start their evaluation in GA animal models.
Looking ahead, Oxurion anticipates finalizing the selection of the top three targets in the fourth quarter of this year and to initiate the lead generation process, aiming to file intellectual property (IP) early 2025.
Pascal Ghoson, CEO of Oxurion, shares his enthusiasm: "By moving beyond traditional approaches focused on the complement pathway alone, our platform has opened new avenues for understanding and treating AMD/GA. The progress we have made paves the way for new therapies in a market estimated to be worth $3-6 billion by 2028. These advances strengthen our position to transform the treatment of retinal degenerative diseases."
About Oxurion
Oxurion
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
Contacts :
| OXURION NV Pascal Ghoson, CEO pascal.ghoson@oxurion.com (mailto:pascal.ghoson@oxurion.com) |
Attachments
- EN (https://ml-eu.globenewswire.com/Resource/Download/6249d63b-c315-4011-bd0b-04bfd9c877bf)
- FR (https://ml-eu.globenewswire.com/Resource/Download/7ab9e1b4-c994-44a5-b1f2-98505b4a9601)
- NL (https://ml-eu.globenewswire.com/Resource/Download/6bb4ec85-bfd8-4e33-ac55-18e3be69b387)
